Ischemic stroke is one of the major diseases of causing adult disability and death.Age,sex,smoking,hypertension,and diabetes,etc.are the risk factors for ischemic stroke,but they can only partially explain the reasons of stroke onset.Twins,families,and single-gene genetic stroke studies have shown that ischemic stroke has obvious genetic predisposition.In recent years,genomics has made remarkable progress in ischemic stroke study and has shown that many new single nucleotide polymorphisms or genes are associated with ischemic stroke and its risk factors.However,the contribution of these genetic genes for ischemic stroke is still too small and the repetitive studies are needed for further confirmation.

Objective To establish the quality standard for Kangyuan Granula. Methods Radix Astragali, Radix Paeoniae Alba, Fructus Lycii and Radix et Rhizoma Glycyrrhizae in this prescription were identified by TLC. The content of the Paeoniflorin was determined by HPLC. The column of AichromBond-AQ-C18 (4.6 mm?150 mm, 5 ?m) was used, the mobile phase was Water-Acetonitrile (85∶15), at the flow of 1.0 mL/min, the column temperature of 30 ℃, and peaks were detected at 230 nm. Results The characteristic of identification by TLC was distinct and highly specific. The linear range of Paeoniflorin was 0.0545～0.545 ?g, r =0.999 5, the average recovery was 97.90%, RSD=1.06% (n =6). Conclusion The method was easy to operate with accurate result and good reproducibility. It can be used effectively for the quality control of this preparation.

Currently targeted therapy of breast cancer therapy has become the hot research field and a kind of brand-new biological treatment mode after three traditional pattern of the surgery, radiotherapy and chemotherapy for breast cancer. Molecular targeted therapy is aimed at the target that may cause cancer cells, such as protocarcinogenic genes and tumor-suppressor genes, cell signaling pathways, cytokines and receptors, antiangiogenesis etc. It can reverse malignant biology behavior to inhibit tumor cell growth from the molecular level and has the advantages of high specific effects and low side effects. This paper focuses on the drug of the molecular targeted therapy for breast cancer and the latest progress of targeted therapy.

OBJECTIVE: To establish a bacterial endotoxin test method for fluorescein sodium injection.METHODS: Based on the bacterial endotoxin test method stated in Chinese Pharmacopoeia 2005 edition(second part),an interference test was conduced on different batches of fluorescein sodium samples using tachypleus amebocyte lysate from different companies.RESULTS: At a concentration of no more than 0.75 mg?mL-1,fluorescein sodium showed no interfere with the bacterial endotoxin test.CONCLUSION: It is feasible for bacterial endotoxin test of fluorescein sodium injection be conducted in a limit value of 0.15 EU?mL-1.

Advances in immunosuppressive therapy have significantly improved short-term allograft and patient survival.However,chronic allograft failure,antibody mediated rejection,recurrent diseases and immunosuppressive drug associated adverse effects remain serious barriers to long-term survival and quality of life.New immunosuppressive agents and protocols are being evaluated to combat these problems.Importantly,clinicians must work to manage post-transplant complications and avoid complex medication regimens,which will potentiate drug interactions and non.compliance.Different organs have different immunogenicities and each recipient has a unique clinical and immunologic profile.The clinician must recognize these variations and customize the immunosuppressive regimens and treatment protocols based on the individual condition.The general principles of an individualized immunosuppressive protocol should take the following factors into account:organ type,donor and recipient characteristics,quality of the donor organ,recipienVs medical history,recipient's undedying disease,immunologic risk for acute rejection,potential co-morbidity related to immunosuppression,significant druginteractions,medication costs and patient compliance.In addition,the combination of immunosuppressive drugs must have a pharmacologic rationale to achieve the desired goal of suppressing the individual's immune system to render the patient tolerant to the allograft while minimizing co-morbidities.For the past few years,many clinical strategies have been applied in an attempt to improve graft survival or to reduce immunsuppressants induced side-effects.Specific protocols include steroid or CNI avoidance,minimization or withdraw,desensitization,and treatment for antibody mediated rejection,disease specific,and pediatric specific.The short-term outcomes from these different strategies are promising but the long-term results remain to be determined.Unfortunately,current immunosuppressive agents or strategies have failed to adequately control chronic rejection in most of solid organ transplantation except liver transplantation.Eady post-transplant complications aye generally related to the operation,the severity of pre-operative illness,immunologic status,and the quality of the donor organ.Careful recipient and donor selection is paramount to minimize severity of disease and medical comorbidities.These early complications include allograft dysfunction,cardiovascular and hemodynamic instability,and immunosuppressive drug-induced adverse effects.Acute infection remains a common and serious early complication despite new and effective drug therapies,placing the responsibility on the clinician for early recognition and treatment.Emerging resistant bacteria and fungi require early and aggressive intervention.Unlike infection,early aUograft rejection is usually limited and manageable with the newer immunosuppressive agents.However,it must be distinguished from other causes of allograft dysfunction(ie.recurrent hepatitis C,ealcineurin induced nephrotoxicity,or infection).Recently approved Cylex@immune cell function assay allows clinicians to tailor and individualize immunosuppression to prevent organ rejection while minimizing infection and complications.Improved patient and allograft survival has enabled transplant recipients to reach milestones and return to productive lives provided they are compliant. It was also challenged the clinician to manage the long-term complications of immunosuppression therapy, adverse drug interaction, recurrent diseases and chronic allograft failure. Long-term immunosuppressive therapy places transplant recipients at risk for renal insufficiency, cardiovascular and metabolic diseases, de novo malignancies, and psychosocial challenges. The management of viral hepatitis C re-infection, chronic allograft nephropathy, vasculopathy, and obliterative bronchiolitis is currently the greatest challenges facing the transplant specialist. The management of immunosuppressants induced adverse effects/drug interactions, chronic allograft failure and recurrent disease is dependent on regular clinical follow-up, an accurate diagnosis and appropriate treatment.Our challenge for the future will be to develop strategies to determine the best, cost-effective regimens for an individual patient to prevent long-term graft loss. I believe the management of immunosuppression and posttransplant complications is best met with a multidisciplinary team approach. This presentation will discuss the current immunosuppressive strategies and the common post-transplant complications. It is designed to help the clinician recognize individual risk factors and provide appropriate management.

Overall there is strong evidence that pharmacdosic therapy of hypertension in patients with diabetes is effective in producing substantial decrease in macrovascular and microvascular diseases.According to clinical evidence and guidelines,patients with diabetes mellitus and hypertension should receive drug treatment in addition to lifestyle/behavioral intervention.Combination therapy of rennin-ansiotensin system inhibitor with calcium channel blocker or low dose thiazide diuretics is quite efficient to reach the blood pressure target.As considering patient compliance with drug therapy,single pill combination may yield more benefits.

OBJECTIVE: To investigate and analyze the epidemiological and etiological characteristics of exercise-related sudden death, so as to provide scientific and effective preventive measures for competitive sports and the body building of the entire people.DATA SOURCES: A computer-based online search of Medline database was conducted to identify articles about exercise-related sudden death published in English between January 1982 and July 2005 by using the keywords of "exercise/sport, sudden death". Meanwhile, Chinese relevant articles at the same period were searched in VIP database with the same keywords in Chinese.STUDY SELECTION: The data were primarily checked, those about exercise-related sudden death were selected, and the repetitive studies and case report were deleted.DATA EXTRACTION: Fourteen of the 63 literatures were involved after classification.DATA SYNTHESIS: Exercise-related sudden death has low incidence and rapid progress, and it has no obvious correlation with the event and intensity of sports, it occurs more in males than in females of 30-60 years.Most of the etiological factors are sudden cardiac death and sudden cerebral death, and coronary atherosclerosis is one of the main causes for exercise-related sudden death.CONCLUSION: Exercise-related sudden death has low incidence, and there is sex characteristics, coronary atherosclerosis is an important factor for exercise-related sudden death. Studies on the epidemiology and etiology of exercise-related sudden death, as well as the preventive measures,should be reinforced.

Objective To observe the effect and safety of orthokeratology in myopia patients.Methods Sixty-eight(136 eyes)young patients with myopia wore orthokeratology lens as research group,and 55 cases(110 eyes)young patients with myopia wore glasses as control group,clinical data of both groups were retrospectively analyzed to evaluate the role of orthokeratology lens on controlling the progression of myopia.Results After treatment,uncorrected visual acuity of research group significantly improved (0.76 ± 0.15 vs.0.40 ± 0.13,P ＜ 0.05),while spherical equivalent(SE)and corneal curvature significantly reduced[(-2.63 ± 1.06)D vs.(-3.52 ± 1.25)D,(42.30 ± 1.25)D vs.(43.21 ± 1.28)D,P ＜ 0.05].After treatment,SE of control group significantly increased[(-4.65 ± 1.29)D vs.(-3.55 ± 1.27)D,P ＜ 0.05],axis oculi significantly prolonged[(25.16 ± 0.55)mm vs.(24.30 ± 0.53)mm,P ＜ 0.05].Research group had no serious corneal infection happened during the treatment.Conclusion Orthokeratology lens can effectively reduce the degree of myopia and slow down the axis oculi growth,and it is used convenient with high security.

Locally advanced non-small cell lung cancer (LA-NSCLC) usually is inoperable because of tumor progress.At present,concurrent chemoradiotherapy has become standard regimen of these patients,which has gotten remarkable effectiveness.This article is a summarization on concurrent chemoradiotherapy for LA-NSCLC.

Objective To explore the clinical value of early arterial phase (EAP) enhanced imaging with MSCT in detecting liver focal lesions.Methods 100 patients with liver focal lesions were examined with MSCT scan.The images were analyzed.Results There were 85.0％ of the 100 cases that demonstrated EAP enhancement,which was hemangioma of liver(100.0％),hepatapostema (100.0％),hepatocellular carcinoma (95.0％),liver metastasis (84.0％),and cholangiocellular carcinoma(25.0％) in descending order.The abnormal vascular lesions and heterogeneous enhancement had high sensitivity and specificity for hepatocellular carcinoma,and the edge nodular enhancement for hemangioma,and the ring enhancement for metastases.Conclusion The EAP enhanced imaging with MSCT in detecting liver focal lesions has great applicative value.